

عنوان مقاله:

Role of Bone Morphogenic Protein2- in femoral head osteonecrosis: a systematic review

محل انتشار:

بیست و ششمین کنگره سالانه انجمن جراحان ارتوپدی ایران (سال: 1397)

تعداد صفحات اصل مقاله: 1

نویسندگان:

Ali Parsa - Massachusetts General Hospital at Harvard Medical School, Boston, USA

Hamed Vahedi - Massachusetts General Hospital at Harvard Medical School, Boston, USA

Karan Goswami - Massachusetts General Hospital at Harvard Medical School, Boston, USA

Arash Aalirezaie - Massachusetts General Hospital at Harvard Medical School, Boston, USA

خلاصه مقاله:

Backgrounds Despite widespread research on non-traumatic femoral head osteonecrosis (FHON), there is no consensus about preventative treatment options. Insufficient blood supply and increased intraosseous pressure are the initiating events in the majority of cases. BMPs are growth factors that belong to the transforming growth factor β (TGF β) superfamily. Two specific formulations of BMPs have already been approved by the FDA: 1. BMP2- (Infused, Medtronic) for the treatment of tibial open fractures and spinal fusion; 2. BMP7- (OP1-, Stryker) in the setting of long bone nonunions. To our knowledge there is no published work reviewing the utility of BMP2- in the setting of FHON. **Methods** online databases (EMBASE, Cochrane, MEDLINE and PubMed) for literature relating to the use of BMP2- in the treatment of FHON on 2nd June 2017. **Results** A total of 169 animal subjects with induced FHON were treated with BMP2- in all the included in vivo studies. In combination, 96 human hips were treated with BMP2- and mean follow-up was at least five years. **Conclusions** The present review of animal and clinical studies concludes that preliminary evidence supports the utilization of BMP2-, and this has an acceptable impact on the midterm outcomes of FHON.

کلمات کلیدی:

لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/826932>

